Lipum AB (publ)
LIPUM.ST
Stockholm Stock Exchange14.35
SEK
+0.10
- -
Lipum AB (publ)
LIPUM.ST
(Stockholm Stock Exchange)
Recent
price
14.35
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Lipum AB (publ) Lipum AB (publ) is a Sweden-based clinical-stage biopharmaceutical company that discovers and develops novel biologic treatments targeting chronic inflammatory diseases, including rheumatoid arthritis, juvenile idiopathic arthritis and other conditions with significant unmet medical needs; its lead product candidate, SOL-116, is a humanized monoclonal antibody that inhibits Bile Salt-Stimulated Lipase (BSSL), a novel immune system target, with demonstrated safety, tolerability, low immunogenicity, predictable pharmacokinetics supporting monthly dosing and pharmacodynamic effects in a completed Phase I trial involving healthy volunteers and mild rheumatoid arthritis patients. The company conducts research and development through collaborations with contract research organizations, scientific advisors and partners such as the Karolinska Institute for BSSL research in rheumatology, Pelago Bioscience AB for drug target monitoring in clinical studies, Örebro University’s Cardiovascular Research Centre, Linköping University for efficacy studies, QPS Netherlands for clinical trial execution and NorthX Biologics for manufacturing; operations are supported by EU grants including Horizon 2020 and Eurostars funding, with headquarters in Umeå at Uminova Science Park since incorporation in 2010 and a lean team of six employees leveraging external expertise for preclinical, clinical and production activities. Lipum maintains ongoing warrant programs (A2/B2 2021/2025 and TO A/B 2025/2028) and convertible loans primarily held by shareholder Flerie Invest AB; in recent developments, Lipum appointed Tobias Helgesson as CFO in August 2025, published its 2024 annual report and Q2 2025 interim report, announced topline results from collaborative efficacy studies and, on November 18 2025, agreed with Flerie AB (publ) on a statutory merger plan under which Lipum will be absorbed by Flerie with operations transferred to a new subsidiary of Flerie Invest AB, valuing Lipum at SEK 338.1 million with a 40% premium to recent trading prices, subject to extraordinary general meetings on December 29 2025, lender set-offs strengthening equity by approximately SEK 43.7 million and regulatory approvals including under Sweden’s FDI Act, paving the way for private funding to advance SOL-116 into a Phase II efficacy trial in moderate-to-severe rheumatoid arthritis patients while Lipum’s shares face delisting from Nasdaq First North Growth Market upon completion expected in Q1 2026.